- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- transferrin-CRM107
- Biological
- Lead sponsor
- Xenova Biomedix
- Industry
- Eligibility
- 5 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Orange, California • Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 5,243
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study, Therapeutic Conventional Surgery
- Other · Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioma, Sarcoma
- Interventions
- SU101
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma
- Interventions
- Radation Therapy
- Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Phase 1, Recurrent Melanoma, Refractory Melanoma
- Interventions
- Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioma
- Interventions
- PEG-interferon alfa-2b, Thalidomide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
- Interventions
- Valproic Acid (VPA), Irinotecan, Simvastatin
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years to 98 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
- Interventions
- IMM-6-415
- Drug
- Lead sponsor
- Immuneering Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, chemotherapy, cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
- Conditions
- Neuroblastoma
- Interventions
- 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Miguel Pampaloni
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Recurrent Melanoma
- Interventions
- selinexor, Correlative studies
- Drug · Other
- Lead sponsor
- Kari Kendra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Sarcoma, Neuroblastoma, Wilm's Tumor
- Interventions
- Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
- Biological · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Mixed Anaplastic Oligoastrocytoma (AOA)
- Interventions
- Plerixafor, Bevacizumab, Surgery
- Drug · Procedure
- Lead sponsor
- Patrick Y. Wen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Glioma
- Interventions
- Mindfulness meditation
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Melanoma
- Interventions
- Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
- Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 4 more
- Conditions
- Unresectable or Metastatic Melanoma
- Interventions
- Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 945 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more
- Conditions
- Central Nervous System Tumor, Pediatric, Neuroblastoma
- Interventions
- temozolomide, thalidomide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- SkylineDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IV Melanoma
- Interventions
- saracatinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Brain Cancer, Malignant Glioma
- Interventions
- radiotherapy (RT) in combination with temozolomide and bevacizumab
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 3
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- R-(-)-gossypol acetic acid, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Baltimore, Maryland + 5 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Patrick Y. Wen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Lebanon, New Hampshire • Winston-Salem, North Carolina + 1 more